FY2024 Earnings Forecast for TNDM Issued By Leerink Partnrs

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Investment analysts at Leerink Partnrs reduced their FY2024 earnings estimates for shares of Tandem Diabetes Care in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings of ($1.78) per share for the year, down from their prior estimate of ($1.71). The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.73) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at $0.01 EPS.

Several other research analysts have also recently commented on TNDM. Piper Sandler reiterated an “overweight” rating and set a $55.00 price target (up previously from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd. Royal Bank of Canada started coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price target for the company. The Goldman Sachs Group started coverage on shares of Tandem Diabetes Care in a report on Friday, October 4th. They set a “neutral” rating and a $46.00 price target for the company. UBS Group upgraded shares of Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Finally, Robert W. Baird lowered their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a report on Thursday, November 7th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Trading Up 2.5 %

Shares of TNDM stock opened at $31.37 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.38 and a current ratio of 2.90. The stock has a market capitalization of $2.06 billion, a P/E ratio of -16.25 and a beta of 1.36. The company has a 50 day moving average price of $38.73 and a 200 day moving average price of $41.91. Tandem Diabetes Care has a fifty-two week low of $14.33 and a fifty-two week high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. The business had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business’s revenue was up 31.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.38) EPS.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of large investors have recently bought and sold shares of TNDM. Allspring Global Investments Holdings LLC raised its position in Tandem Diabetes Care by 1,567.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,635 shares of the medical device company’s stock worth $235,000 after buying an additional 6,237 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Tandem Diabetes Care by 4.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 34,506 shares of the medical device company’s stock worth $1,222,000 after purchasing an additional 1,493 shares during the period. Texas Permanent School Fund Corp grew its stake in shares of Tandem Diabetes Care by 1.6% during the 1st quarter. Texas Permanent School Fund Corp now owns 56,910 shares of the medical device company’s stock worth $2,015,000 after purchasing an additional 915 shares during the period. Quantbot Technologies LP acquired a new position in shares of Tandem Diabetes Care during the 1st quarter worth $710,000. Finally, SG Americas Securities LLC acquired a new position in shares of Tandem Diabetes Care during the 1st quarter worth $5,227,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.